Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

The Potential Role of C-peptide in Sexual and Reproductive Functions in Type 1 Diabetes Mellitus: An Update

Author(s): Roberta Pujia, Samantha Maurotti, Adriana Coppola, Stefano Romeo, Arturo Pujia and Tiziana Montalcini*

Volume 18, Issue 1, 2022

Published on: 30 December, 2021

Article ID: e051021196983 Pages: 8

DOI: 10.2174/1573399817666211005093434

Price: $65

Abstract

Background: Although hyperglycaemia is known to be the leading cause of diabetic complications, the beneficial effect of optimal glucose control in preventing diabetic complications is still far from being proven. In fact, such complications may not be related to glycaemic control alone.

Objective: This review summarizes several studies that suggest that a C-peptide deficiency could be new and common pathophysiology for complications in type 1 diabetes, including sexual and reproductive dysfunction.

Methods: We reviewed in vitro, in vivo, and human studies on the association between C-peptide deficiency or C-peptide replacement therapy and complications in type 1 diabetes. It seems that Cpeptide replacement therapy may interrupt the connection between diabetes and sexual/reproductive dysfunction.

Results: The Diabetes Control and Complications Trial suggested that maintaining C-peptide secretion is associated with a reduced incidence of retinopathy, nephropathy, and hypoglycaemia. Risk of vascular, hormonal, and neurologic damage in the structures supplying blood to the penis increases with increasing levels of HbA1. However, several human studies have suggested an association between C-peptide production and hypothalamic/pituitary functions. When exposed to C-peptide, cavernosal smooth muscle cells increase the production of nitric oxide. C-peptide in diabetic rats improves sperm count, sperm motility, testosterone levels, and nerve conduction compared to non-treated diabetic rats.

Conclusion: C-peptide deficiency may be involved, at least partially, in the development of several pathological features associated with type 1 diabetes, including sexual/reproductive dysfunction. Preliminary studies have reported that C-peptide administration protects against diabetic microand macrovascular damages as well as sexual/reproductive dysfunction. Therefore, further studies are needed to confirm these promising findings.

Keywords: C-peptide, type 1 diabetes, sexual dysfunction, erectile dysfunction, reproductive dysfunction, hyperglycaemia.

[1]
Šimonienė D, Platūkiene A, Prakapienė E, Radzevičienė L, Veličkiene D. Insulin resistance in type 1 diabetes mellitus and its association with patient’s micro- and macrovascular complications, sex hormones, and other clinical data. Diabetes Ther 2020; 11(1): 161-74.
[http://dx.doi.org/10.1007/s13300-019-00729-5] [PMID: 31792784]
[2]
Livingstone SJ, Looker HC, Hothersall EJ, et al. Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLoS Med 2012; 9(10): e1001321.
[http://dx.doi.org/10.1371/journal.pmed.1001321] [PMID: 23055834]
[3]
Cleland SJ, Fisher BM, Colhoun HM, Sattar N, Petrie JR. Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks? Diabetologia 2013; 56(7): 1462-70.
[http://dx.doi.org/10.1007/s00125-013-2904-2] [PMID: 23613085]
[4]
Daka B, Rosen T, Jansson PA, Råstam L, Larsson CA, Lindblad U. Inverse association between serum insulin and sex hormone-binding globulin in a population survey in Sweden. Endocr Connect 2012; 2(1): 18-22.
[http://dx.doi.org/10.1530/EC-12-0057] [PMID: 23781314]
[5]
Bruns CM, Kemnitz JW. Sex hormones, insulin sensitivity, and diabetes mellitus. ILAR J 2004; 45(2): 160-9.
[http://dx.doi.org/10.1093/ilar.45.2.160] [PMID: 15111735]
[6]
Matsui H, Sopko NA, Hannan JL, Bivalacqua TJ. Pathophysiology of erectile dysfunction. Curr Drug Targets 2015; 16(5): 411-9.
[http://dx.doi.org/10.2174/138945011605150504114041] [PMID: 25950641]
[7]
Bizzarri C, Benevento D, Giannone G, et al. Sexual dimorphism in growth and insulin-like growth factor-I in children with type 1 diabetes mellitus. Growth Horm IGF Res 2014; 24(6): 256-9.
[http://dx.doi.org/10.1016/j.ghir.2014.08.004] [PMID: 25175911]
[8]
Nathan DM, Genuth S, Lachin J, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14): 977-86.
[http://dx.doi.org/10.1056/NEJM199309303291401] [PMID: 8366922]
[9]
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837-53.
[http://dx.doi.org/10.1016/S0140-6736(98)07019-6] [PMID: 9742976]
[10]
Charonis AS, Reger LA, Dege JE, et al. Laminin alterations after in vitro nonenzymatic glycosylation. Diabetes 1990; 39(7): 807-14.
[http://dx.doi.org/10.2337/diab.39.7.807] [PMID: 2113013]
[11]
Galliera E, Marazzi MG, Gazzaruso C, et al. Evaluation of circulating sRAGE in osteoporosis according to BMI, adipokines and fracture risk: a pilot observational study. Immun Ageing 2017; 14: 13.
[http://dx.doi.org/10.1186/s12979-017-0097-0] [PMID: 28630637]
[12]
Schmidt AM, Hori O, Chen JX, et al. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest 1995; 96(3): 1395-403.
[http://dx.doi.org/10.1172/JCI118175] [PMID: 7544803]
[13]
Kuhlencordt PJ, Gyurko R, Han F, et al. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 2001; 104(4): 448-54.
[http://dx.doi.org/10.1161/hc2901.091399] [PMID: 11468208]
[14]
Kobayashi T, Tahara Y, Matsumoto M, et al. Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest 2004; 114(6): 784-94.
[http://dx.doi.org/10.1172/JCI200421446] [PMID: 15372102]
[15]
Cartledge JJ, Eardley I, Morrison JF. Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes. BJU Int 2001; 87(4): 402-7.
[http://dx.doi.org/10.1046/j.1464-410x.2001.00067.x] [PMID: 11251537]
[16]
Kengne AP, Patel A, Colagiuri S, et al. The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study. Diabetologia 2010; 53(5): 821-31.
[http://dx.doi.org/10.1007/s00125-010-1681-4] [PMID: 20157695]
[17]
Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360(2): 129-39.
[http://dx.doi.org/10.1056/NEJMoa0808431] [PMID: 19092145]
[18]
Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360(24): 2503-315.
[19]
Forsén L, Meyer HE, Midthjell K, Edna TH. Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trøndelag Health Survey. Diabetologia 1999; 42(8): 920-5.
[http://dx.doi.org/10.1007/s001250051248] [PMID: 10491750]
[20]
Gunczler P, Lanes R, Paz-Martinez V, et al. Decreased lumbar spine bone mass and low bone turnover in children and adolescents with insulin dependent diabetes mellitus followed longitudinally. J Pediatr Endocrinol Metab 1998; 11(3): 413-9.
[http://dx.doi.org/10.1515/JPEM.1998.11.3.413] [PMID: 11517957]
[21]
Campos Pastor MM, López-Ibarra PJ, Escobar-Jiménez F, Serrano Pardo MD, García-Cervigón AG. Intensive insulin therapy and bone mineral density in type 1 diabetes mellitus: a prospective study. Osteoporos Int 2000; 11(5): 455-9.
[http://dx.doi.org/10.1007/s001980070114] [PMID: 10912849]
[22]
Lachin JM, McGee P, Palmer JP. Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial. Diabetes 2014; 63(2): 739-48.
[http://dx.doi.org/10.2337/db13-0881] [PMID: 24089509]
[23]
Hansen A, Johansson BL, Wahren J, von Bibra H. C-peptide exerts beneficial effects on myocardial blood flow and function in patients with type 1 diabetes. Diabetes 2002; 51(10): 3077-82.
[http://dx.doi.org/10.2337/diabetes.51.10.3077] [PMID: 12351450]
[24]
Forst T, Kunt T, Pohlmann T, et al. Biological activity of C-peptide on the skin microcirculation in patients with insulin-dependent diabetes mellitus. J Clin Invest 1998; 101(10): 2036-41.
[http://dx.doi.org/10.1172/JCI2147] [PMID: 9593759]
[25]
Gur S, Peak TC, Kadowitz PJ, Sikka SC, Hellstrom WJ. Review of erectile dysfunction in diabetic animal models. Curr Diabetes Rev 2014; 10(1): 61-73.
[http://dx.doi.org/10.2174/1573399809666131126151024] [PMID: 24295372]
[26]
Kouidrat Y, Pizzol D, Cosco T, et al. High prevalence of erectile dysfunction in diabetes: a systematic review and meta- analysis of 145 studies. Diabet Med 2017; 34(9): 1185-92.
[http://dx.doi.org/10.1111/dme.13403] [PMID: 28722225]
[27]
Bellastella G, Maiorino MI, Olita L, Della Volpe E, Giugliano D, Esposito K. Premature ejaculation is associated with glycemic control in Type 1 diabetes. J Sex Med 2015; 12(1): 93-9.
[http://dx.doi.org/10.1111/jsm.12755] [PMID: 25424355]
[28]
Zamponi V, Mazzilli R, Bitterman O, et al. Association between type 1 diabetes and female sexual dysfunction. BMC Womens Health 2020; 20(1): 73.
[http://dx.doi.org/10.1186/s12905-020-00939-1] [PMID: 32299459]
[29]
Pontiroli AE, Cortelazzi D, Morabito A. Female sexual dysfunction and diabetes: a systematic review and meta-analysis. J Sex Med 2013; 10(4): 1044-51.
[http://dx.doi.org/10.1111/jsm.12065] [PMID: 23347454]
[30]
ADA Standards of Medical Care in Diabetes. Diab Care 2018; 41(-Supp 1)
[31]
Wessells H, Penson DF, Cleary P, et al. Effect of intensive glycemic therapy on erectile function in men with type 1 diabetes. J Urol 2011; 185(5): 1828-34.
[http://dx.doi.org/10.1016/j.juro.2010.12.098] [PMID: 21420129]
[32]
Kamenov ZA. A comprehensive review of erectile dysfunction in men with diabetes. Exp Clin Endocrinol Diabetes 2015; 123(3): 141-58.
[PMID: 25502583]
[33]
Biswas M, Hampton D, Newcombe RG, Rees DA. Total and free testosterone concentrations are strongly influenced by age and central obesity in men with type 1 and type 2 diabetes but correlate weakly with symptoms of androgen deficiency and diabetes-related quality of life. Clin Endocrinol (Oxf) 2012; 76(5): 665-73.
[http://dx.doi.org/10.1111/j.1365-2265.2011.04196.x] [PMID: 21854402]
[34]
van Dam EW, Dekker JM, Lentjes EG, et al. Steroids in adult men with type 1 diabetes: a tendency to hypogonadism. Diabetes Care 2003; 26(6): 1812-8.
[http://dx.doi.org/10.2337/diacare.26.6.1812] [PMID: 12766115]
[35]
Holt SK, Lopushnyan N, Hotaling J, et al. Prevalence of low testosterone and predisposing risk factors in men with type 1 diabetes mellitus: findings from the DCCT/EDIC. J Clin Endocrinol Metab 2014; 99(9): E1655-60.
[http://dx.doi.org/10.1210/jc.2014-1317] [PMID: 25013994]
[36]
Gibbins I. Functional organization of autonomic neural pathways. Organogenesis 2013; 9(3): 169-75.
[http://dx.doi.org/10.4161/org.25126] [PMID: 23872517]
[37]
Braffett BH, Wessells H, Sarma AV. Urogenital Autonomic Dysfunction in Diabetes. Curr Diab Rep 2016; 16(12): 119.
[http://dx.doi.org/10.1007/s11892-016-0824-5] [PMID: 27766580]
[38]
Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989; 320(16): 1025-30.
[http://dx.doi.org/10.1056/NEJM198904203201601] [PMID: 2927481]
[39]
Rabago Rodriguez R, Gómez-Díaz RA, Tanus Haj J, et al. Carotid intima-media thickness in pediatric type 1 diabetic patients. Diabetes Care 2007; 30(10): 2599-602.
[http://dx.doi.org/10.2337/dc07-0922] [PMID: 17644614]
[40]
McDonald TO, Gerrity RG, Jen C, et al. Diabetes and arterial extracellular matrix changes in a porcine model of atherosclerosis. J Histochem Cytochem 2007; 55(11): 1149-57.
[http://dx.doi.org/10.1369/jhc.7A7221.2007] [PMID: 17652266]
[41]
Wang P, Xu YY, Lv TT, et al. Subclinical atherosclerosis in patients with type 1 diabetes mellitus: a systematic review and meta--analysis. Angiology 2019; 70(2): 141-59.
[http://dx.doi.org/10.1177/0003319718787366] [PMID: 30009613]
[42]
Chiurlia E, D’Amico R, Ratti C, Granata AR, Romagnoli R, Modena MG. Subclinical coronary artery atherosclerosis in patients with erectile dysfunction. J Am Coll Cardiol 2005; 46(8): 1503-6.
[http://dx.doi.org/10.1016/j.jacc.2005.06.068] [PMID: 16226175]
[43]
Gazzaruso C, Solerte SB, Pujia A, Coppola A, Vozzelli M, Salvucci F, et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with asymptomatic coronary artery disease angiographically proven. A potential protective role for statins and 5-phosphodiesterase inhibitors. J Am Coll Cardiol 2008; 51(21): 2040-4.
[http://dx.doi.org/10.1016/j.jacc.2007.10.069] [PMID: 18498958]
[44]
Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294(23): 2996-3002.
[http://dx.doi.org/10.1001/jama.294.23.2996] [PMID: 16414947]
[45]
Gazzaruso C, Coppola A, Giustina A. Erectile dysfunction and coronary artery disease in patients with diabetes. Curr Diabetes Rev 2011; 7(2): 143-7.
[http://dx.doi.org/10.2174/157339911794940693] [PMID: 21348816]
[46]
Gazzaruso C, Coppola A, Montalcini T, et al. Screening for asymptomatic coronary artery disease can reduce cardiovascular mortality and morbidity in type 2 diabetic patients. Intern Emerg Med 2012; 7(3): 257-66.
[http://dx.doi.org/10.1007/s11739-011-0527-5] [PMID: 21298361]
[47]
Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 2006; 55(5): 1463-9.
[http://dx.doi.org/10.2337/db05-1423] [PMID: 16644706]
[48]
Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010; 57(5): 804-14.
[http://dx.doi.org/10.1016/j.eururo.2010.02.020] [PMID: 20189712]
[49]
Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: A randomized controlled trial. JAMA 1999; 281(5): 421-6.
[http://dx.doi.org/10.1001/jama.281.5.421] [PMID: 9952201]
[50]
Safarinejad MR. Oral sildenafil in the treatment of erectile dysfunction in diabetic men: a randomized double-blind and placebocontrolled study. J Diabetes Complications 2004; 18(4): 205-10.
[http://dx.doi.org/10.1016/S1056-8727(03)00056-4] [PMID: 15207837]
[51]
Ziegler D, Merfort F, Van Ahlen H, Yassin A, Reblin T, Neureither M. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med 2006; 3(5): 883-91.
[http://dx.doi.org/10.1111/j.1743-6109.2006.00295.x] [PMID: 16942532]
[52]
Meeking DR, Fosbury JA, Cummings MH. Sexual dysfunction and sexual health concerns in women with diabetes. Pract Diabetes 2013; 30: 327-31.
[http://dx.doi.org/10.1002/pdi.1805]
[53]
Nyirjesy P, Sobel JD. Genital mycotic infections in patients with diabetes. Postgrad Med 2013; 125(3): 33-46.
[http://dx.doi.org/10.3810/pgm.2013.05.2650] [PMID: 23748505]
[54]
Kim NN, Stankovic M, Cushman TT, Goldstein I, Munarriz R, Traish AM. Streptozotocin-induced diabetes in the rat is associated with changes in vaginal hemodynamics, morphology and biochemical markers. BMC Physiol 2006; 6: 4.
[http://dx.doi.org/10.1186/1472-6793-6-4] [PMID: 16734901]
[55]
Jangir RN, Jain GC. Diabetes mellitus induced impairment of male reproductive functions: a review. Curr Diabetes Rev 2014; 10(3): 147-57.
[http://dx.doi.org/10.2174/1573399810666140606111745] [PMID: 24919656]
[56]
Enzlin P, Mathieu C, Van Den Bruel A, Vanderschueren D, Demyttenaere K. Prevalence and predictors of sexual dysfunction in patients with type 1 diabetes. Diabetes Care 2003; 26(2): 409-14.
[http://dx.doi.org/10.2337/diacare.26.2.409] [PMID: 12547871]
[57]
Bucci D, Rodriguez-Gil JE, Vallorani C, Spinaci M, Galeati G, Tamanini C. GLUTs and mammalian sperm metabolism. J Androl 2011; 32(4): 348-55.
[http://dx.doi.org/10.2164/jandrol.110.011197] [PMID: 21088231]
[58]
Yang J, Cummings EA, O’connell C, Jangaard K. Fetal and neonatal outcomes of diabetic pregnancies. Obstet Gynecol 2006; 108(3 Pt 1): 644-50.
[http://dx.doi.org/10.1097/01.AOG.0000231688.08263.47] [PMID: 16946226]
[59]
Mallidis C, Agbaje I, O’Neill J, McClure N. The influence of type 1 diabetes mellitus on spermatogenic gene expression. Fertil Steril 2009; 92(6): 2085-7.
[http://dx.doi.org/10.1016/j.fertnstert.2009.06.006] [PMID: 19589518]
[60]
Dorman JS, Steenkiste AR, Foley TP, et al. Menopause in type 1 diabetic women: Is it premature? Diabetes 2001; 50(8): 1857-62.
[http://dx.doi.org/10.2337/diabetes.50.8.1857] [PMID: 11473049]
[61]
Yeshaya A, Orvieto R, Dicker D, Karp M, Ben-Rafael Z. Menstrual characteristics of women suffering from insulin-dependent diabetes mellitus. Int J Fertil Menopausal Stud 1995; 40(5): 269-73.
[PMID: 8556032]
[62]
Jonasson JM, Brismar K, Sparén P, et al. Fertility in women with type 1 diabetes: a population-based cohort study in Sweden. Diabetes Care 2007; 30(9): 2271-6.
[http://dx.doi.org/10.2337/dc06-2574] [PMID: 17563340]
[63]
Livshits A, Seidman DS. Fertility issues in women with diabetes. Womens Health (Lond Engl) 2009; 5(6): 701-7.
[http://dx.doi.org/10.2217/WHE.09.47] [PMID: 19863473]
[64]
Snajderová M, Martínek J, Horejsí J, Nováková D, Lebl J, Kolousková S. Premenarchal and postmenarchal girls with insulin-dependent diabetes mellitus: ovarian and other organ-specific autoantibodies, menstrual cycle. J Pediatr Adolesc Gynecol 1999; 12(4): 209-14.
[65]
Rigler R, Pramanik A, Jonasson P, et al. Specific binding of proinsulin C-peptide to human cell membranes. Proc Natl Acad Sci USA 1999; 96(23): 13318-23.
[http://dx.doi.org/10.1073/pnas.96.23.13318] [PMID: 10557318]
[66]
Ohtomo Y, Bergman T, Johansson BL, Jörnvall H, Wahren J. Differential effects of proinsulin C-peptide fragments on Na+, K+-ATPase activity of renal tubule segments. Diabetologia 1998; 41(3): 287-91.
[http://dx.doi.org/10.1007/s001250050905] [PMID: 9541168]
[67]
Nordquist L, Shimada K, Ishii T, Furuya DT, Kamikawa A, Kimura K. Proinsulin C-peptide prevents type-1 diabetes-induced decrease of renal Na+-K+-ATPase alpha1-subunit in rats. Diabetes Metab Res Rev 2010; 26(3): 193-9.
[http://dx.doi.org/10.1002/dmrr.1071] [PMID: 20225182]
[68]
Wahren J, Ekberg K, Johansson J, et al. Role of C-peptide in human physiology. Am J Physiol Endocrinol Metab 2000; 278(5): E759-68.
[http://dx.doi.org/10.1152/ajpendo.2000.278.5.E759] [PMID: 10780930]
[69]
Kaplan JH. Biochemistry of Na,K-ATPase. Annu Rev Biochem 2002; 71: 511-35.
[http://dx.doi.org/10.1146/annurev.biochem.71.102201.141218] [PMID: 12045105]
[70]
Féraille E, Doucet A. Sodium-potassium-adenosinetriphosphatase-dependent sodium transport in the kidney: hormonal control. Physiol Rev 2001; 81(1): 345-418.
[http://dx.doi.org/10.1152/physrev.2001.81.1.345] [PMID: 11152761]
[71]
Suhail M. Na, K-ATPase: ubiquitous multifunctional transmembrane protein and its relevance to various pathophysiological conditions. J Clin Med Res 2010; 2(1): 1-17.
[http://dx.doi.org/10.4021/jocmr2010.02.263w] [PMID: 22457695]
[72]
Raccah D, Fabreguetts C, Azulay JP, Vague P. Erythrocyte Na(+)-K(+)-ATPase activity, metabolic control, and neuropathy in IDDM patients. Diabetes Care 1996; 19(6): 564-8.
[http://dx.doi.org/10.2337/diacare.19.6.564] [PMID: 8725852]
[73]
De La Tour DD, Raccah D, Jannot MF, Coste T, Rougerie C, Vague P. Erythrocyte Na/K ATPase activity and diabetes: relationship with C-peptide level. Diabetologia 1998; 41(9): 1080-4.
[http://dx.doi.org/10.1007/s001250051033] [PMID: 9754827]
[74]
Djemli-Shipkolye A, Gallice P, Coste T, et al. The effects ex vivo and in vitro of insulin and C-peptide on Na/K adenosine triphosphatase activity in red blood cell membranes of type 1 diabetic patients. Metabolism 2000; 49(7): 868-72.
[http://dx.doi.org/10.1053/meta.2000.6753] [PMID: 10909997]
[75]
Kitamura T, Kimura K, Jung BD, et al. Proinsulin C-peptide activates cAMP response element-binding proteins through the p38 mitogen-activated protein kinase pathway in mouse lung capillary endothelial cells. Biochem J 2002; 366(Pt 3): 737-44.
[http://dx.doi.org/10.1042/bj20020344] [PMID: 12059784]
[76]
Lindahl E, Nyman U, Melles E, et al. Cellular internalization of proinsulin C-peptide. Cell Mol Life Sci 2007; 64(4): 479-86.
[http://dx.doi.org/10.1007/s00018-007-6467-6] [PMID: 17279313]
[77]
Al-Rasheed NM, Meakin F, Royal EL, et al. Potent activation of multiple signalling pathways by C-peptide in opossum kidney proximal tubular cells. Diabetologia 2004; 47(6): 987-97.
[http://dx.doi.org/10.1007/s00125-004-1404-9] [PMID: 15164168]
[78]
Russo C, Lazzaro V, Gazzaruso C, et al. Proinsulin C-peptide modulates the expression of ERK1/2, type I collagen and RANKL in human osteoblast-like cells (Saos-2). Mol Cell Endocrinol 2017; 442: 134-41.
[http://dx.doi.org/10.1016/j.mce.2016.12.012] [PMID: 28007656]
[79]
Kitamura T, Kimura K, Jung BD, et al. Proinsulin C-peptide rapidly stimulates mitogen-activated protein kinases in Swiss 3T3 fibroblasts: requirement of protein kinase C, phosphoinositide 3-kinase and pertussis toxin-sensitive G-protein. Biochem J 2001; 355(Pt 1): 123-9.
[http://dx.doi.org/10.1042/bj3550123] [PMID: 11256956]
[80]
Li H, Xu L, Dunbar JC, Dhabuwala CB, Sima AA. Effects of Cpeptide on expression of eNOS and iNOS in human cavernosal smooth muscle cells. Urology 2004; 64(3): 622-7.
[http://dx.doi.org/10.1016/j.urology.2004.05.005] [PMID: 15351621]
[81]
Forst T, Kunt T. Effects of C-peptide on microvascular blood flow and blood hemorheology. Exp Diabesity Res 2004; 5(1): 51-64.
[http://dx.doi.org/10.1080/15438600490424532] [PMID: 15198371]
[82]
Li L, Oshida Y, Kusunoki M, et al. Rat C peptide I and II stimulate glucose utilization in STZ-induced diabetic rats. Diabetologia 1999; 42(8): 958-64.
[http://dx.doi.org/10.1007/s001250051254] [PMID: 10491756]
[83]
DiSanto ME. Corpus cavernosum smooth muscle physiology: a role for sex hormones? J Androl 2003; 24(6)(Suppl.): S6-S16.
[http://dx.doi.org/10.1002/j.1939-4640.2003.tb02742.x] [PMID: 14581491]
[84]
Wagoner K, Sanchez G, Nguyen AN, Enders GC, Blanco G. Different expression and activity of the alpha1 and alpha4 isoforms of the Na,K-ATPase during rat male germ cell ontogeny. Reproduction 2005; 130(5): 627-41.
[http://dx.doi.org/10.1530/rep.1.00806] [PMID: 16264093]
[85]
Darszon A, Acevedo JJ, Galindo BE, et al. Sperm channel diversity and functional multiplicity. Reproduction 2006; 131(6): 977-88.
[http://dx.doi.org/10.1530/rep.1.00612] [PMID: 16735537]
[86]
Sjöberg S, Gunnarsson R, Gjötterberg M, Lefvert AK, Persson A, Ostman J. Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987; 30(4): 208-13.
[http://dx.doi.org/10.1007/BF00270417] [PMID: 3297896]
[87]
Suzuki K, Watanabe K, Motegi T, Kajinuma H. High prevalence of proliferative retinopathy in diabetic patients with low pancreatic B-cell capacity. Diabetes Res Clin Pract 1989; 6(1): 45-52.
[http://dx.doi.org/10.1016/0168-8227(89)90056-9] [PMID: 2649341]
[88]
Winocour PH, Jeacock J, Kalsi P, Gordon C, Anderson DC. The relevance of persistent C-peptide secretion in type 1 (insulin-dependent) diabetes mellitus to glycaemic control and diabetic complications. Diabetes Res Clin Pract 1990; 9(1): 23-35.
[http://dx.doi.org/10.1016/0168-8227(90)90005-E] [PMID: 2351037]
[89]
Forst T, De La Tour DD, Kunt T, et al. Effects of proinsulin Cpeptide on nitric oxide, microvascular blood flow and erythrocyte Na+,K+-ATPase activity in diabetes mellitus type I. Clin Sci (Lond) 2000; 98(3): 283-90.
[http://dx.doi.org/10.1042/CS19990241] [PMID: 10677386]
[90]
Johansson BL, Borg K, Fernqvist-Forbes E, Odergren T, Remahl S, Wahren J. C-peptide improves autonomic nerve function in IDDM patients. Diabetologia 1996; 39(6): 687-95.
[http://dx.doi.org/10.1007/BF00418540] [PMID: 8781764]
[91]
Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med 2000; 17(3): 181-9.
[http://dx.doi.org/10.1046/j.1464-5491.2000.00274.x] [PMID: 10784221]
[92]
Ekberg K, Brismar T, Johansson BL, Jonsson B, Lindström P, Wahren J. Amelioration of sensory nerve dysfunction by C-Peptide in patients with type 1 diabetes. Diabetes 2003; 52(2): 536-41.
[http://dx.doi.org/10.2337/diabetes.52.2.536] [PMID: 12540632]
[93]
Wahren J, Foyt H, Daniels M, Arezzo JC. Long-acting Cpeptide and neuropathy in type 1 diabetes: a 12-month clinical trial. Diabetes Care 2016; 39(4): 596-602.
[http://dx.doi.org/10.2337/dc15-2068] [PMID: 26884473]
[94]
Johansson BL, Sjöberg S, Wahren J. The influence of human Cpeptide on renal function and glucose utilization in type 1 (insulin-dependent) diabetic patients. Diabetologia 1992; 35(2): 121-8.
[http://dx.doi.org/10.1007/BF00402543] [PMID: 1547915]
[95]
Sjöquist M, Huang W, Johansson BL. Effects of C-peptide on renal function at the early stage of experimental diabetes. Kidney Int 1998; 54(3): 758-64.
[http://dx.doi.org/10.1046/j.1523-1755.1998.00074.x] [PMID: 9734600]
[96]
Johansson BL, Linde B, Wahren J. Effects of C-peptide on blood flow, capillary diffusion capacity and glucose utilization in the exercising forearm of type 1 (insulin-dependent) diabetic patients. Diabetologia 1992; 35(12): 1151-8.
[http://dx.doi.org/10.1007/BF00401369] [PMID: 1478367]
[97]
Maurotti S, Russo C, Musolino V, et al. Effects of C-Peptide Replacement Therapy on Bone Microarchitecture Parameters in Streptozotocin-Diabetic Rats. Calcif Tissue Int 2020; 107(3): 266-80.
[http://dx.doi.org/10.1007/s00223-020-00716-0] [PMID: 32607636]
[98]
Nazmy WH, Elbassuoni EA, Ali FF, Rifaai RA. Proinsulin C-peptide as an alternative or combined treatment with insulin for management of testicular dysfunction and fertility impairments in streptozotocin-induced type 1 diabetic male rats. J Cell Physiol 2019; 234(6): 9351-7.
[http://dx.doi.org/10.1002/jcp.27618] [PMID: 30317639]
[99]
Ahangarpour A, Oroojan AA, Ramezani A. Effects of c-peptide and nicotinamide on serum LH, FSH, testosterone levels and sperm count in nicotinamide/ streptozotocin-induced-diabetes in mice. Acta Endocrinol (Bucur) 2014; 10(4): 588-94.
[http://dx.doi.org/10.4183/aeb.2014.588]
[100]
Valeggia CR, Ellison PT. Impact of breastfeeding on anthropometric changes in peri-urban Toba women (Argentina). Am J Hum Biol 2003; 15(5): 717-24.
[http://dx.doi.org/10.1002/ajhb.10202] [PMID: 12953184]
[101]
Würzburger MI, Prelevic GM, Sönksen PH, Peric LA, Till S, Morris RW. Effects of improved blood glucose on insulin-induced hypoglycaemia, TRH, GnRH and exercise tests in insulin-dependent diabetes. Clin Endocrinol (Oxf) 1990; 32(6): 799-807.
[http://dx.doi.org/10.1111/j.1365-2265.1990.tb00927.x] [PMID: 2116947]
[102]
Coiro V, Volpi R, Marchesi C, et al. Influence of residual C-peptide secretion on nocturnal serum TSH peak in well-controlled diabetic patients. Clin Endocrinol (Oxf) 1997; 47(3): 305-10.
[http://dx.doi.org/10.1046/j.1365-2265.1997.2501063.x] [PMID: 9373451]
[103]
Wu F, Ames R, Evans MC, France JT, Reid IR. Determinants of sex hormone-binding globulin in normal postmenopausal women. Clin Endocrinol (Oxf) 2001; 54(1): 81-7.
[http://dx.doi.org/10.1046/j.1365-2265.2001.01183.x] [PMID: 11167930]
[104]
Bezemer ID, Rinaldi S, Dossus L, et al. C-peptide, IGF-I, sex-steroid hormones and adiposity: a cross-sectional study in healthy women within the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Causes Control 2005; 16(5): 561-72.
[http://dx.doi.org/10.1007/s10552-004-7472-9] [PMID: 15986111]
[105]
Sim HG, Kliot M, Lange PH, Ellis WJ, Takayama TK, Yang CC. Two-year outcome of unilateral sural nerve interposition graft after radical prostatectomy. Urology 2006; 68(6): 1290-4.
[http://dx.doi.org/10.1016/j.urology.2006.08.1064] [PMID: 17141842]
[106]
Singh H, Karakiewicz P, Shariat SF, et al. Impact of unilateral interposition sural nerve grafting on recovery of urinary function after radical prostatectomy. Urology 2004; 63(6): 1122-7.
[http://dx.doi.org/10.1016/j.urology.2004.01.016] [PMID: 15183964]
[107]
Montalcini T, Pujia A, Donini LM, et al. A call to action: now is the time to screen elderly and treat osteosarcopenia, a position paper of the italian college of academic nutritionists med/49 (ican-49). Nutrients 2020; 12(9): 2662.
[http://dx.doi.org/10.3390/nu12092662] [PMID: 32878316]

Rights & Permissions Print Cite
Article Metrics
20
1
© 2024 Bentham Science Publishers | Privacy Policy